Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Has Consensus Price Target of $63.50 According to Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $60.20.

A number of brokerages have recently weighed in on SUPN. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Jefferies Financial Group began coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Finally, Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $47.00 price objective on the stock.

Get Our Latest Stock Report on Supernus Pharmaceuticals

Hedge Funds Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. GW&K Investment Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 32.5% during the third quarter. GW&K Investment Management LLC now owns 1,374,198 shares of the specialty pharmaceutical company’s stock valued at $49,265,000 after acquiring an additional 336,956 shares in the last quarter. Stephens Investment Management Group LLC boosted its holdings in Supernus Pharmaceuticals by 10.2% in the third quarter. Stephens Investment Management Group LLC now owns 1,638,047 shares of the specialty pharmaceutical company’s stock worth $58,724,000 after purchasing an additional 152,226 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Supernus Pharmaceuticals by 2.2% in the 3rd quarter. Royce & Associates LP now owns 40,385 shares of the specialty pharmaceutical company’s stock worth $1,448,000 after buying an additional 860 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 235.3% in the third quarter. Russell Investments Group Ltd. now owns 287,607 shares of the specialty pharmaceutical company’s stock worth $10,311,000 after acquiring an additional 201,840 shares during the period. Finally, Maryland State Retirement & Pension System increased its holdings in Supernus Pharmaceuticals by 52.2% during the third quarter. Maryland State Retirement & Pension System now owns 12,842 shares of the specialty pharmaceutical company’s stock valued at $460,000 after buying an additional 4,402 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ SUPN opened at $29.45 on Friday. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of 8.23, a P/E/G ratio of 0.58 and a beta of 0.84. Supernus Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $42.81. The stock’s 50-day moving average is $40.10 and its 200 day moving average is $46.50.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.14). Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The firm had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. During the same period in the prior year, the company earned ($0.80) EPS. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts forecast that Supernus Pharmaceuticals will post 3.80 EPS for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The business also recently announced a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were given a $8.13 dividend.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.

See Also

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.